Werewolf Therapeutics Inc (HOWL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Werewolf Therapeutics Inc (HOWL) has a cash flow conversion efficiency ratio of 0.407x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($6.63 Million) by net assets ($16.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Werewolf Therapeutics Inc (HOWL) total market value for the company's overall valuation and market capitalisation.
Werewolf Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Werewolf Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Werewolf Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Werewolf Therapeutics Inc ranked by their cash flow conversion efficiency. Explore how high is Werewolf Therapeutics Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Toro Energy Ltd
AU:TOE
|
-0.245x |
|
INFOvine co. Ltd
KQ:115310
|
0.021x |
|
Beyaz Filo Oto Kiralama AS
IS:BEYAZ
|
0.347x |
|
Simula Technology
TWO:3511
|
0.013x |
|
Annovis Bio Inc
NYSE:ANVS
|
-2.883x |
|
Ram-On Investments and Holdings Ltd
TA:RMN
|
-0.001x |
|
Live Verdure Ltd
AU:LV1
|
-0.448x |
|
Alpha Holdings Inc
KQ:117670
|
-0.065x |
Annual Cash Flow Conversion Efficiency for Werewolf Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Werewolf Therapeutics Inc from 2019 to 2025. View today's stock price for Werewolf Therapeutics Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $24.80 Million | $-60.29 Million | -2.431x | -217.48% |
| 2024-12-31 | $73.39 Million | $-56.19 Million | -0.766x | -161.46% |
| 2023-12-31 | $111.37 Million | $-32.61 Million | -0.293x | +11.76% |
| 2022-12-31 | $122.34 Million | $-40.60 Million | -0.332x | -18.25% |
| 2021-12-31 | $152.79 Million | $-42.88 Million | -0.281x | -34.43% |
| 2020-12-31 | $89.22 Million | $-18.62 Million | -0.209x | +78.63% |
| 2019-12-31 | $9.77 Million | $-9.54 Million | -0.977x | -- |
About Werewolf Therapeutics Inc
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies throu… Read more